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Background: Non-invasive measures of vascular reactivity have emerged to refine cardiovascular risk. However,
limited data exists investigating vascular reactivity as a preoperative diagnostic tool for anesthesiologists. In this
study, we compare the utility of two non-invasive techniques, Brachial Artery Reactivity Testing (BART) and Digital
Thermal Monitoring (DTM), as surrogates for measuring vascular reactivity.
Methods: Following IRB approval, 26 patients scheduled for major thoracic surgery (e.g. esophagectomy and
pneumonectomy) were studied prospectively. BART [Flow mediated dilation (FMD) and Peak flow velocity (PFV)]
and DTM [Temperature rebound (TR%)] were performed preoperatively at baseline using 5 minute blood pressure
cuff occlusion of the upper arm. Statistical summaries were provided for the comparison of BART and DTM with
select patient characteristics, and correlations were used to investigate the strength of the relationship between
BART and DTM measurements.
Results: Patients preoperatively diagnosed with hyperlipidemia were associated with lower FMD% values {Median
(Range): 14.8 (2.3, 38.1) vs. 6.2 (0.0, 14.3); p = 0.006}. There were no significant associations between BART and DTM
techniques in relation to cardiovascular risk factors or postoperative complications.
Conclusion: Our study suggests that impaired vascular reactivity as measured by BART is associated with the
incidence of hyperlipidemia. Also, using a novel technique such as DTM may provide a simpler and more accessible
point of care testing for vascular reactivity in a perioperative setting. Both non-invasive techniques assessing
vascular function warrant further refinement to better assist preoperative optimization strategies aimed at improving
perioperative vascular function.
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Postoperative cardiovascular events are responsible for a
substantial proportion of the morbidity and mortality of
patients undergoing non-cardiac surgery [1]. With the
availability of many practical lifestyle and pharmaco-
logical interventions that can be directed at patients with
an increased risk of vascular complications (i.e. smoking
cessation, exercise or statin therapy [2]), early identifica-
tion of these patients has long been of interest to clinicians* Correspondence: robert.schier@gmx.net
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unless otherwise stated.in order to prevent postoperative complications [3,4]. Re-
cently, non-invasive measures of vascular function have
gained increasing importance, as they are used in addition
to standard cardiovascular disease (CVD) risk factors in
an attempt to refine risk stratification in patients undergo-
ing non-cardiac surgery [5]. However, these measures are
technically challenging and not ideal for clinical purposes,
especially if serial measurements are required [6].
Brachial Artery Reactivity Testing (BART) is a non-
invasive technique that has been established over the past
few years for the evaluation of preclinical disease states
geared at improving vascular function with targeted specific
interventions and risk factor modifications [7]. Unfortunately,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Schier et al. BMC Anesthesiology 2014, 14:47 Page 2 of 10
http://www.biomedcentral.com/1471-2253/14/47assessing flow-mediated dilation (FMD) and peak flow vel-
ocity (PFV) requires technical expertise and ultrasound
equipment. Hence, it is restricted to the setting of a vascu-
lar laboratory. A novel technique that is currently under
investigation in clinical trials is Digital Thermal Monitor-
ing (DTM). This non-invasive method is currently under
evaluation for the assessment of peripheral vascular func-
tion and improvement of cardiovascular risk assessment
[8,9]. Similar to FMD measured by ultrasound, this method
measures changes in skin blood flow induced by reactive
hyperemia by utilizing a temperature rebound (TR) [10].
Controversy remains whether there is a correlation present
between macrovascular- measured via ultrasound in theFigure 1 Representative example of a temperature – time trace withibrachial artery (FMD), and predominantly microvascular
hyperemic responses- measured at the fingertip via (DTM)
or pulse waveform analysis.
A recent study investigating pulse waveform analysis
refuted the claims that large (macrovascular) and small
(microvascular) arterial stiffness are surrogate measures
for sonographic assessments of brachial FMD [11].
The aim of this study was to evaluate two non-invasive
techniques (BART and DTM) for the preoperative assess-
ment of vascular function. Outcome parameters consisted
of the two tested techniques with cardiovascular risk factors
such as: hypertension, diabetes, hyperlipidemia, obesity,
smoking and the incidence of postoperative complications.n the DTM assessment.
Table 1 List of DTM parameters
Temperature (T) in Celsius (°C)
TMPi Initial fingertip temperature at cuff inflation
TMPmin Lowest temperature (nadir) observed after cuff inflation
TMPmax Highest temperature observed after cuff deflation
Time (t) in seconds (s)
Ti Time to cuff inflation
Tmin Time of TMPmin
Tmax Time of TMPmax
Derived parameters
TF Temperature Fall (°C; TMPmax – TMPi)
TR°C Temperature Rebound (°C; TMPmax - TMPi)
TR% Temperature Rebound (%; (TR°C/TMPi)*100)
NP Nadir to Peak (°C; TMPmax – TMPmin)
SLP Slope (°C/s; NP/Time to Reach TR)
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The study was approved by the local Ethics Committee
(The University of Texas M.D. Anderson Cancer Center,
approval number 2003–0434) and all patients signed an
informed consent. Thirty patients undergoing major thor-
acic surgery (lobectomy, pneumonectomy, esophagectomy)
were eligible consented for this prospective observational
study. We chose major thoracic surgery patients due to
their high incidence of cardiovascular risk factors and post-
operative cardiovascular complications (e.g. postoperative
morbidity of 15-36% and mortality of 4.8-10.9% following
pneumonectomy) [4,12].
Four patients had to be excluded due to low baseline
fingertip temperature at the start of the DTM assess-
ment. Therefore, a total of twenty-six consecutive pa-
tients with thoracic cancer (i.e. pulmonary, esophageal
cancer) participated in this study. Other exclusion cri-
teria included: being under 18 years of age, pregnant, the
presence of a recent or unstable myocardial infarction,
cerebrovascular accident, pulmonary embolus, deep vein
thrombosis, or any condition that deemed the patient
unsatisfactory for surgery.
Brachial Artery Reactivity Testing (BART)
Patients were tested preoperatively within one week of
undergoing surgery. With patients in a fasting state and
in a supine position, ultrasound measurements of the
brachial artery were performed in a quiet, dark room
under stable temperature conditions (25°C). Resting
blood pressure was measured by placing a blood pres-
sure cuff on the right forearm. One operator blinded to
the study patients’ medical history obtained right arm
brachial artery ultrasound images (Philips Excelera, An-
dover, MA 01810, USA) at baseline and at 30, 60, 90 and
120 seconds after a 5 minute occlusion with 50 mmHg
above systolic blood pressure. Post-occlusion FMD (in
mm) and PFV (in cm/sec) were expressed in percent
diameter and flow increase- absolute values were also re-
corded. Patients were grouped into low, medium, and
high tertiles according to the increase of FMD and PFV
values following arm occlusion.
Digital Thermal Monitoring (DTM)
DTM measurements were performed subsequent to FMD
measurements, with at least 10 minutes between each
procedure. After an overnight fast and abstinence from to-
bacco, alcohol, and caffeine, patients, in a supine position,
were tested in a quiet, dark room under stable temperature
conditions (25°C). DTM was measured using the VENDYS®
5000BC device (Endothelix Inc., Houston, TX, USA),
which utilizes a computer-based thermometry system
(0.01°C thermal resolution) and two fingertip thermocouple
probes attached to the index finger of each hand (left:
occlusion; right: control). Standard sphygmomanometercuffs were placed on each upper arm (left: occlusion;
right: control). After a period of stabilization of basal
skin temperature, the right cuff was rapidly inflated
to ≥ 50 mmHg above systolic blood pressure (measured
on control arm). After a 5 minute arm occlusion the cuff
was then rapidly deflated and a temperature rebound
(TR%) was measured in the right index finger in response
to the invoked reactive hyperemia for 5 minutes. A repre-
sentative example of a temperature/time trace and a list of
the measured DTM parameters are shown in the Figure 1
and Table 1.
Perioperative risk assessment
Patient data was obtained using the clinical database
(ClinicStation™). In addition, patients’ perioperative risk
profile was assessed using established pre-operative risk
scores from the American Society of Anesthesiologists
(ASA) Physical Status Classification System, the Modi-
fied Lee Cardiac Risk Index, and the American Heart
Association/American College of Cardiology (ACC/AHA)
Risk Score). Two blinded investigators collected data
about perioperative events according to standardized cri-
teria. Patients were monitored during their hospital stay,
approximately 30 days, and 6 months after surgery. Post-
operative events were evaluated according to predefined
adverse event categories and definitions (Additional file 1).
Statistical analysis
Descriptive statistics consisting of means and standard
deviations, medians and ranges, or frequencies and per-
cents were used to summarize our patients’ data. Based
on a previous study [13], we assumed a change in bra-
chial artery diameter before and after forearm ischemia
of 17.8 ± 10.9% (4.0 ± 0.6 mm at rest vs. 4.7 ± 0.6 mm at
60 sec.) after cuff deflation would be a detectable difference
Table 2 Summary of patient characteristics
Characteristics All patients N = 26
Age in years
Mean ± SD, (Range) 59.3 ± 10.4, (28, 78)
Female sex 9 (35%)
Caucasian 20 (77%)
Length of Hospital Stay in days
Mean ± SD, (Range) 11.5 ± 17.8, (2, 77)
Length of ICU Stay in days








≤ 1 23 (89%)






































ASA = American Society of Anesthesiologists physical status classification
system; AT2 = Antagonist.
*BMI >30 kg/m2.
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sided paired t-test). For purposes of conducting exploratory
analyses, select patient variables were converted to categor-
ical variables by splitting the data at the median value thus
creating a variable with two levels. Continuous measures of
FMD%, PFV%, TR%, and TR(°C) were then compared be-
tween the levels of these patient characteristics using t-test
or the Wilcoxon rank-sum test, if more appropriate. A cor-
relation analysis was used to evaluate the bivariate relation-
ship between BART and DTM parameters. For the DTM
measurements, we excluded tests with a baseline fingertip
temperature below 27°C in reference to a previous study
indicating that it would provide an unreliable temperature
rebound (TR) value due to predisposed vasoconstriction
in a relatively cold finger [10].
Multivariate analyses were not undertaken due to the
study’s small sample size. A p-value less than 0.05 was
considered statistically significant.
Results
Clinical characteristics of the subjects (n = 26; age, 59 ±
10 years; range, 28–78) are shown in Table 2. Patients
with hyperlipidemia were associated with lower FMD%
values {Median (Range): 14.8 (2.3, 38.1) vs. 6.2 (0.0,
14.3); p = 0.006, Table 3). Patients with other preopera-
tive cardiac risk factors (smoking, obesity, hypertension,
diabetes, preoperative chemo-/radiation therapy) or classi-
fied with an ASA, Lee Cardiac Risk Index or ACC/AHA
score greater than 2 did not differ in FMD%, PFV% and
TR%-values when compared to the rest of the study group
(Tables 3 and 4). Preoperative cardiovascular medication
(statin, ACE-inhibitor, AT2-inhibitor or beta-blocker ther-
apy) did not have an impact on BART or DTM values
(Tables 3 and 4). Neither BART nor DTM were signifi-
cantly related to the incidence of postoperative complica-
tion (Table 5). Neither FMD% nor PFV% were significantly
correlated with TR% (Table 6). However, postoperative
complications were associated with a longer length of
hospital stay (29.7 ± 31.7 vs. 6.0 ± 4.3 days; p = 0.002).
Table 3 Summary of patient characteristics by BART parameters
FMD% PFV%
Characteristics N Mean ± SD Median (Range) p-value* N Mean ± SD Median (Range) p-value*
Age
<60 15 12.8 ± 9.0 12.5 (0, 38.1) 0.795 15 103.1 ± 64.2 90 (10, 291) 0.243
>60 11 11.9 ± 9.5 11.1 (0, 29.7) 11 78.0 ± 50.6 81 (21, 175)
Sex
Male 17 11.3 ± 7.4 11.1 (0, 29.7) 0.418 17 102.0 ± 65.3 90 (10, 291) 0.346
Female 9 14.6 ± 11.6 14.8 (0, 38.1) 9 74.4 ± 42.6 60 (21, 139)
Smoker
No 9 11.0 ± 11.9 10.3 (0, 38.1) 0.293 9 82.9 ± 46.9 96 (10, 139) 0.979
Yes 17 13.2 ± 7.4 14.3 (0, 29.7) 17 97.5 ± 65.4 85 (21, 291)
Length of stay
<5 12 12.9 ± 8.2 12.2 (0, 29.7) 0.554 12 76.9 ± 40.1 83.5 (21, 139) 0.304
>5 14 12.0 ± 9.9 10.45 (0, 38.1) 14 105.8 ± 70.2 93.5 (10, 291)
Obesity
No 16 12.9 ± 10.2 11.5 (0, 38.1) 0.958 16 87.6 ± 38.1 88.5 (10, 145) 1.00
Yes 10 11.7 ± 7.3 12.3 (0, 22.2) 10 100.3 ± 84.6 76 (21, 291)
Chemotherapy
No 13 15.8 ± 9.3 11.9 (6.2, 38.1) 0.117 13 75.0 ± 40.2 85 (10, 139) 0.191
Yes 13 9.1 ± 7.7 8.9 (0, 20.5) 13 109.9 ± 70.6 98 (30, 291)
Radiotherapy
No 15 15.4 ± 9.5 12.5 (0, 38.1) 0.058 15 78.4 ± 46.4 85 (10, 175) 0.243
Yes 11 8.4 ± 6.8 8.9 (0, 18.9) 11 111.6 ± 70.7 98 (30, 291)
ASA Score
2 2 11.4 ± 7.4 11.45 (6.2, 16.7) ** 2 29.5 ± 27.6 29.5 (10, 49) **
3 24 12.5 ± 9.3 11.5 (0, 38.1) 24 97.7 ± 58.2 89.5 (21, 291)
Lee Cardiac Risk Index
2 25 12.7 ± 9.1 11.9 (0, 38.1) ** 25 95.8 ± 57.8 89 (21, 291) **
3 1 6.2 ± NA 6.2 (6.2, 6.2) 1 10.0 ± NA 10 (10, 10)
ACC/AHA Risk Score
≤2 23 12.6 ± 9.3 11.9 (0, 38.1) ** 23 94.1 ± 57.2 89 (21, 291) **
>2 2 6.8 ± 0.9 6.85 (6.2, 7.5) 2 32.0 ± 31.1 32 (10, 54)
Diabetes Mellitus
No 23 12.4 ± 9.4 11.9 (0, 38.1) ** 23 91.4 ± 57.6 88 (21, 291) **
Yes 3 12.3 ± 7.4 10.3 (6.2, 20.5) 3 100.3 ± 83.6 116 (10, 175)
Hypertension
No 12 16.1 ± 9.1 13.4 (7.5, 38.1) 0.089 12 90.0 ± 33.9 89 (26, 145) 0.719
Yes 14 9.3 ± 8.0 8.25 (0, 22.2) 14 94.6 ± 75.6 85.5 (10, 291)
Hyperlipidemia
No 17 15.6 ± 9.0 14.8 (2.3, 38.1) 0.006 17 90.4 ± 45.8 89 (21, 175) 0.571
Yes 9 6.4 ± 5.5 6.2 (0, 14.3) 9 96.4 ± 81.7 82 (10, 291)
Statin Therapy
No 20 13.8 ± 9.6 13.4 (0, 38.1) 0.120 20 90.7 ± 44.0 89.5 (21, 175) 0.429
Yes 6 7.9 ± 5.2 8 (0, 14.3) 6 98.3 ± 100.2 81.5 (10, 291)
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Table 3 Summary of patient characteristics by BART parameters (Continued)
ACE-Inhibitor Therapy
No 23 13.2 ± 9.3 12.5 (0, 38.1) ** 23 93.4 ± 59.7 88 (21, 291) **
Yes 3 6.5 ± 3.7 6.2 (3, 10.3) 3 85.0 ± 65.3 116 (10, 129)
AT2-Inhibitor Therapy
No 25 12.2 ± 9.2 11.1 (0, 38.1) ** 25 94.2 ± 59.6 89 (10, 291) **
Yes 1 16.7 ± NA 16.7 (16.7, 16.7) 1 49.0 ± NA 49 (49, 49)
Beta-Blocker Therapy
No 20 12.9 ± 9.8 12.2 (0, 38.1) 0.670 20 94.0 ± 61.3 89.5 (21, 291) 0.808
Yes 6 10.9 ± 6.1 8.9 (5.1, 20.5) 6 87.5 ± 55.9 85 (10, 175)
*p-value from Wilcoxon rank-sum test.
**p-value not provided if ≤ 3 observations in a group.
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The aim of our study is to evaluate the utility of BART
and DTM, two different techniques with similar end-
points, for the preoperative assessment of vascular func-
tion in patients presenting at the anesthesia clinic. Both
techniques utilize the principle of indirectly measuring
reactive hyperemia in response to arm occlusion. Our
study indicated that both techniques were comparable
with respect to preoperative cardiovascular risk factors
(i.e. hypertension, diabetes, obesity, smoking) and the
incidence of postoperative complications. However, pa-
tients with hyperlipidemia were found to be associated
with significantly lower FMD% values as measured by
BART.
In a clinical setting, non-invasive techniques assessing
vascular function need to meet certain criteria in order
to be established as practicable tools. They need to be
reproducible and relatively easy to administer before
they are recommended for widespread use. The predict-
ive value of non-invasive vascular function measure-
ments concerning perioperative morbidity and mortality
has been controversial over the last years. Especially in
non-cardiac surgery where there is a growing need for
risk prediction, non-invasive techniques have yet to be
established as useful tools in improving clinical out-
comes. An increasing population of patients with cardio-
vascular risk factors (i.e. metabolic syndrome) serves as
a counteracting force towards this dilemma. The success
of either technique (BART and DTM) will depend on
their ability to reliably measure an individual’s vascular
function and to be added to the standard preoperative
cardiovascular examinations thus refining therapeutic
strategies which, in turn, will have a positive effect on
postoperative outcomes.
BART studies have shown impaired vasodilatory re-
sponses in patients with cardiovascular risk factors such
as hypertension [14,15], diabetes mellitus [16], hyperchol-
esterolemia [17], and smoking [18]. In asymptomatic pa-
tients, a prospective study investigating DTM suggestedthat this method correlated with certain risk factors iden-
tified in the Framingham Risk Score [19]. In our study,
DTM variables trended toward an association between
lower BART and DTM values in patients with risk factors
and higher risk scores described by: hypertension requir-
ing therapy, diabetes, hyperlipidemia requiring statin ther-
apy, Lee Cardiac Risk Index ≤2, and ACC/AHA Risk
Score ≤2, but this failure to reach statistical significance
should not preclude further investigation of these non-
invasive techniques.
BART – Strengths and weaknesses
One of the strengths of BART is that it is non-invasive
and its repeatable use is applicable for monitoring the
progress of atherosclerosis, especially in cardiac patients.
In a prospective trial (N = 135), FMD was the strongest
predictor of re-stenosis in patients undergoing stent im-
plantation [20]. Although a large study (N = 444) sug-
gests that measures of vascular reactivity do not have
additional prognostic use in patients at high risk [6], the
ability of FMD to monitor vascular function in response
to therapy has been described in the literature [21-23]. A
limitation of BART is its technical challenge with a sig-
nificant learning curve to achieve high quality and con-
sistent performance. Preparation and proper positioning
of the patient and the sonographer ensure ergonomic
comfort while minimizing both stress-related fatigue
during the scan period and error [7]. Furthermore, in-
consistencies in the published studies [24-27] highlight
some of the difficulties of applying FMD technique in
the setting of diabetes. Other confounders of FMD in-
clude arm length, sex, and postprandial state. Thus,
comparison between groups of patients should use
standard experimental conditions and, if possible, ensure
that baseline vessel diameter and baseline blood flow are
similar [28]. In our study we had similar conditions in
both laboratory rooms when testing BART and DTM,
patients were in the fasting state, and baseline vessel
diameter and baseline blood flow were similar among
Table 4 Summary of Patient Characteristics by DMT Parameters
TR% TR (°C)
Characteristics N Mean ± SD Median (Range) p-value002A N Mean ± SD Median (Range) p-value*
Age
<60 15 −0.17 ± 0.95 −0.24 (−1.95, 2.01) 0.392 15 −0.05 ± 0.31 −0.08 (−0.63, 0.66) 0.421
>60 11 −0.01 ± 1.44 0.38 (−2.69, 2.02) 11 −0.02 ± 0.47 0.13 (−0.91, 0.63)
Sex
Male 17 0.19 ± 1.02 0.04 (−1.7, 2.02) 0.125 17 0.06 ± 0.33 0.01 (−0.54, 0.66) 0.112
Female 9 −0.66 ± 1.26 −0.51 (−2.69, 1.09) 9 −0.22 ± 0.42 −0.18 (−0.91, 0.37)
Smoker
No 9 0.42 ± 1.09 0.51 (−1.6, 2.02) 0.090 9 0.13 ± 0.35 0.17 (−0.53, 0.63) 0.100
Yes 17 −0.38 ± 1.13 −0.19 (−2.69, 2.01) 17 −0.12 ± 0.37 −0.06 (−0.91, 0.66)
Length of Stay
<5 12 −0.18 ± 1.39 0.19 (−2.69, 2.01) 0.797 12 −0.06 ± 0.46 0.07 (−0.91, 0.66) 0.758
>5 14 −0.04 ± 0.98 −0.16 (−1.95, 2.02) 14 −0.02 ± 0.31 −0.05 (−0.63, 0.63)
Obesity
No 16 −0.27 ± 1.28 −0.14(−2.69, 2.01) 0.429 16 −0.09 ± 0.42 −0.05 (−0.91, 0.66) 0.493
Yes 10 0.17 ± 0.93 −0.08 (−1.43, 2.02) 10 0.05 ± 0.30 −0.03 (−0.47, 0.63)
Chemotherapy
No 13 −0.27 ± 0.93 −0.04 (−1.7, .79) 0.663 13 −0.09 ± 0.30 −0.01 (−0.54, 0.26) 0.663
Yes 13 0.06 ± 1.37 −0.12 (−2.69, 2.02) 13 0.01 ± 0.45 −0.04 (−0.91, 0.66)
Radiotherapy
No 15 −0.57 ± 1.11 −0.24 (−2.69, .79) 0.052 15 −0.19 ± 0.36 −0.08 (−0.91, 0.26) 0.052
Yes 11 0.54 ± 0.93 0.26 (−.41, 2.02) 11 0.17 ± 0.29 0.09 (−0.14, 0.66)
ASA Score
2 2 −0.46 ± 1.37 −0.46 (−1.43, .51) ** 2 −0.15 ± 0.45 −0.15 (−0.47, 0.17) **
3 24 −0.07 ± 1.17 −0.08 (−2.69, 2.02) 24 −0.03 ± 0.38 −0.03 (−0.91, 0.66)
Lee Cardiac Risk Index
2 25 −0.13 ± 1.18 −0.12 (−2.69, 2.02) ** 25 −0.05 ± 0.38 −0.04 (−0.91, 0.66) **
3 1 0.51 ± NA 0.51(.51, .51) 1 0.17 ± NA 0.17 (0.17, 0.17)
ACC/AHA Risk Score
≤2 23 −0.13 ± 1.23 −0.19 (−2.69, 2.02) ** 23 −0.05 ± .4 −0.06 (−0.91, 0.66) **
>2 2 0.23 ± 0.39 0.24 (−.04, .51) 3 0.04 ± .11 −0.01 (−0.04, 0.17)
Diabetes Mellitus
No 23 −0.12 ± 1.23 −0.04 (−2.69, 2.02) ** 23 −0.04 ± 0.40 −0.01 (−0.91, 0.66) **
Yes 3 0.05 ± 0.40 −0.12 (−.24, .51) 3 0.02 ± 0.13 −0.04 (−0.08, 0.17)
Hypertension
No 12 −0.45 ± 1.04 −0.25 (−2.69, .79) 0.165 12 −0.15 ± 0.35 −0.08 (−0.91, 0.26) 0.181
Yes 14 0.20 ± 1.21 0.19 (−1.95, 2.02) 14 0.06 ± 0.39 0.07 (−0.63, 0.66)
Hyperlipidemia
No 17 −0.23 ± 1.09 −0.12 (−2.69, 2.02) 0.467 17 −0.08 ± 0.36 −0.04 (−0.91, 0.63) 0.435
Yes 9 0.14 ± 1.32 0.38 (−1.95, 2.01) 9 0.04 ± 0.42 0.13 (−0.63, 0.66)
Statin Therapy
No 20 −0.24 ± 1.14 −0.16 (−2.69, 2.02) 0.301 20 −0.08 ± 0.36 −0.05 (−0.91, 0.63) 0.273
Yes 6 0.34 ± 1.23 0.45 (−1.6, 2.01) 6 0.12 ± 0.41 0.15 (−0.53, 0.66)
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Table 4 Summary of Patient Characteristics by DMT Parameters (Continued)
ACE-Inhibitor Therapy
No 23 −0.13 ± 1.23 −0.12 (−2.69, 2.02) ** 23 −0.05 ± 0.40 −0.04 (−0.91, 0.66) **
Yes 3 0.10 ± 0.38 0.04 (−0.24, 0.51) 3 0.03 ± 0.13 0.01 (−0.08, 0.17)
AT2-Inhibitor Therapy
No 25 −0.05 ± 1.15 −0.04 (−2.69, 2.02) ** 25 −0.02 ± 0.37 −0.01 (−0.91, 0.66) **
Yes 1 −1.43 ± NA −1.43 (−1.43, −1.43) 1 −0.47 ± NA −0.47 (−0.47, −0.47)
Beta-Blocker Therapy
No 20 −0.22 ± 1.23 −0.07 (−2.69, 2.02) 0.503 20 −0.08 ± 0.40 −0.03 (−0.91,0 .63) 0.465
Yes 6 0.30 ± 0.89 −0.08 (−0.31, 2.01) 6 0.10 ± 0.29 −0.03 (−0.10, 0.66)
*p-value from Wilcoxon rank-sum test.
**p-value not provided if ≤ 3 observations in a group.
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51.7 cm/sec).
DTM - Strengths and weaknesses
The advantage of DTM is that ultrasound is replaced by
measurements of fingertip thermal changes; thereby,
providing a technique that is simpler and more access-
ible as a point of care test (POCT). It facilitates research
into the perioperative kinetics of vascular reactivity fol-
lowing surgery, especially in the postoperative period
where patients are often restricted to the postoperative
recovery area (e.g. intensive care unit or surgical floor).
In a recent study, a low DTM signal was found in pa-
tients with certain cardiovascular risk factors (abdominal
obesity, smoking) [29]. Another study demonstrated that
fingertip thermal response as measured by DTM was in-
versely related to increasing cardiovascular riskTable 5 BART and DTM measures by complication
Complications*
Yes (N = 6) No (N = 20) p-value
BART Parameters
FMD
Mean ± SD 6.6 ± 4.4 14.2 ± 9.4 0.07
Median (Range) 8.2 (0, 11.1) 14.3 (0, 38.1)
PFV
Mean ± SD 84.7 ± 39.0 94.8 ± 64.5 0.72
Median (Range) 85.0 (31, 138) 89.0 (10, 291)
DTM Parameters
TR%
Mean ± SD 0.38 ± 1.20 −0.25 ± 1.20 0.25
Median (Range) 0.17 (−1.24, 2.02) −0.20 (−2.70, 2.00)
TR (°C)
Mean ± SD 0.12 ± 0.35 −0.08 ± 0.38 0.27
Median (Range) 0.06 (−0.38, 0.63) −0.06 (−0.91, 0.66)
*Postoperative Cardiac, Pulmonary, Wound Healing and Surgical Events.independent of age, sex and other cardiac risk factors
[9]. Reactive hyperemia after a period of upper arm is-
chemia is a physiologic response of the vasculature, de-
pending on an endothelium-derived nitric oxide release,
resulting in a rapid increase in blood flow and temperature
[30,31]. DTM, utilizing this predominantly microvascular
response, may be a useful point-of-care tool for the assess-
ment of vascular function perioperatively. Furthermore, it
may serve as a contributory marker of postoperative vas-
cular function that has been reported to be impaired by
systemic inflammation [32].
Limitations
There are differences in physics between the two tech-
niques with BART measuring vascular diameter and blood
flow and DTM measuring temperature as a surrogate
marker of blood flow. However, both techniques utilize
the principle of reactive hyperemia after a period of ische-
mia, which is a known physiologic response of the vascu-
lature and endothelial system resulting in rapid increases
in both local blood flow and temperature [30,31,33,34].
DTM is highly dependent on ambient room temperature
and the adjustment of the temperature probe to the sur-
rounding condition. A stable equilibration time is required
in order to avoid a temperature drift throughout the test
that would have an impact on TF and TR. Also, vasocon-
striction results from a cuff placed too tightly around the
arm leading to false TF and TR values. This is not the only
effector and other contributing factors may come from a
cold fingertip (<27°C), a stressor like the white coat effectTable 6 Correlation of BART vs. DTM Parameters
BART (N = 26) DTM (N = 26) Pearson Correlation
Parameters Parameters r p-value
FMD% TR% −0.36 0.07
TR (°C) −0.36 0.07
PFV% TR% −0.10 0.63
TR (°C) −0.10 0.63
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http://www.biomedcentral.com/1471-2253/14/47[35,36], a myogenically mediated vasoconstriction, a rise
in intravascular pressure, or even a direct damming of
venous outflow and capillary outflow obstruction [37].
Furthermore, the extent a neurovascular response is in-
volved in the measurement of reactive hyperemia re-
mains unclear. Infrared imaging of the control hand
during DTM testing revealed this phenomenon, which
possibly leads to blunting of the temperature response
to reactive hyperemia. Evaluation of the temperature data
of the left finger, functioning as a control, might give add-
itional value to observation although its interpretation has
not been fully understood.
A further limitation of our study is that the sample
size of our prospective, observational study is quite low.
One of our pilot studies [38] investigating BART in a
surgical population identified an optimal sample size of
N = 165 patients is required to have adequate power for
identifying the predictive value of BART for postoperative
complications in future studies. Unfortunately, we were
not able to achieve this sample size in our study.
Conclusion
To our knowledge this is the first study comparing the
utility of two non-invasive techniques (BART and DTM)
for the preoperative assessment of vascular function.
Impaired vascular reactivity as measured by BART was
associated with the incidence of hyperlipidemia but not
with other preoperative cardiac risk factors or the inci-
dence of postoperative complications. Although, non-
invasive techniques assessing vascular function warrant
further refinement, we conclude that BART and DTM
are useful diagnostic tools for assisting preoperative
optimization strategies aimed at improving vascular
function in patients undergoing major surgery.
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